Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis

Nephrology Dialysis Transplantation

Volumn 24, Issue 1, 2009, Pages 278-285

  Evenepoel, Pieter ^a   Selgas, Rafael ^b   Caputo, Flavia ^c   Foggensteiner, Lukas ^d   Heaf, James G ^e   Ortiz, Alberto ^f   Kelly, Alison ^g   Chasan Taber, Scott ^h   Duggal, Ajay ^g   Fan, Stanley ⁱ  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Ospedale Civico e Benfratelli   (Italy)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^g Genzyme Europe Research   (United Kingdom)

^h GENZYME CORPORATION   (United States)

ⁱ ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Hyperphosphataemia; Peritoneal dialysis; Phosphate binders; Sevelamer hydrochloride

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CALCIUM ACETATE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER; URIC ACID;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PERITONITIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ACETATES; ADULT; AGED; CALCIUM COMPOUNDS; CHELATING AGENTS; DRUG TOLERANCE; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PHOSPHORUS; POLYAMINES;

EID: 58049208291     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn488     Document Type: Article

References (36)

1. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
2. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793
3. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
4. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942
5. Ammirati AL, Dalboni MA, Cendoroglo M et al. Coronary artery calcification, systemic inflammationmarkers andmineral metabolism in a peritoneal dialysis population. Nephron Clin Pract 2006; 104: c33-c40
6. Noordzij M, Korevaar JC, Bos WJ et al. Mineral metabolism and cardiovascular morbidity and mortality risk - peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 2006; 21: 2513-2520
7. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
8. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
9. Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland 1999-2002. Nephrol Dial Transplant 2004; 19: 2584-2591
10. Hotchkiss JR, Hermsen ED, Hovde LB et al. Dynamic analysis of peritoneal dialysis associated peritonitis. ASAIO J 2004; 50: 568-576
11. Verger C, Ryckelynck JP, Duman M et al. French peritoneal dialysis registry (RDPLF): outline and main results. Kidney Int Suppl 2006; 103: S12-S20
12. Stompor TP, Pasowicz M, Sulowicz W et al. Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am J Kidney Dis 2004; 44: 517-528
13. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
14. ERA-EDTA Registry. ERA-EDTA Registry 2004 Annual Report. Amsterdam, The Netherlands: Academic Medical Center, Department of Medical Informatics, 2006
15. U.S. Renal Data System. 2006 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: USRDS, 2006
16. Mahdavi H, Kuizon BD, Gales B et al. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 2003; 18: 1260-1264
17. Ortiz A, Rios F, Melero R et al. Experience with sevelamer in peritoneal dialysis. Nefrologia 2003; 23: 432-436
18. Salusky IB, Goodman WG, Sahney S et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16: 2501-2508
19. Pieper AK, Haffner D, Hoppe B et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 2006; 47: 625-635
20. Katopodis KP, Andrikos EK, Gouva CD et al. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int 2006; 26: 320-327
21. Raggi P, James G, Burke SK et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20: 764-772
22. Ferreira A, Frazao JM, Faugere M-C et al. Effects of sevelamer and calcium carbonate on bone mineralisation and turnover in chronic maintenance haemodialysis patients [Abstract MO016]. Nephrol Dial Transplant 2006; 21(Suppl 4): iv293
23. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol Dial Transplant 2004; 19(Suppl 1): i9-i13
24. De Smet R, Thermote F, Lamiere N et al. Sevelamer hydrochloride (Renagel) adsorbs the uremic compounds indoxyl sulfate, indole and P-cresol [Abstract]. J Am Soc Nephrol 2004; 15: 505
25. Nii-Kono T, Iwasaki Y, Uchida M et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007; 71: 738-743
26. Ferramosca E, Burke S, Chasan-Taber S et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-925
27. Yamada K, Fujimoto S, Tokura T et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 2005; 27: 361-365
28. Castro R, Herman A, Ferreira C et al. RenaGel efficacy in severe secondary hyperparathyroidism. Nefrologia 2002; 22: 448-455
29. Garg JP, Chasan-Taber S, Blair A et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 2005; 52: 290-295
30. Kahvecioglu S, Akdag I, Kiyici M et al. High prevalence of irritable bowel syndrome and upper gastrointestinal symptoms in patients with chronic renal failure. J Nephrol 2005; 18: 61-66
31. Xue JL, Chen SC, Ebben JP et al. Peritoneal and hemodialysis: I. Differences in patient characteristics at initiation. Kidney Int 2002; 61: 734-740
32. Wang AY, Woo J, Sea MM et al. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications? Am J Kidney Dis 2004; 43: 712-720
33. Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69: 1726-1732
34. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-932
35. Winchester JF, Rotellar C, Goggins M et al. Calcium and phosphate balance in dialysis patients. Kidney Int Suppl 1993; 41: S174-S178
36. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004; 62: 104-115